This study looks at the safety of two drugs, bictegravir and lenacapavir, for kids and teens with HIV-1. HIV-1 is a virus that attacks the immune system. The study is for those already on a complex antiretroviral (ARV) treatment, which means they take more than one pill a day to control the virus. Participants need to have very low virus levels in their blood, which means their current treatment is working well.
The study will measure if the doses of the drugs are safe and how they work in the body over 24 weeks. The study is open to children and teens aged 2 to 18, depending on their weight. However, if someone has a very low CD4 cell count (a type of white blood cell important for fighting infections), or certain other health issues like hepatitis, they cannot join.
- Study lasts for 24 weeks with regular check-ups.
- Participants must have low HIV levels and no resistance to certain drugs.
- Study focuses on safety and drug effects in the body.
Participants will be closely monitored for any side effects and how well the drugs work together.